Natalizumab for the treatment of relapsing multiple sclerosis

References

• BalcerLJGalettaSLCalabresiPA2007Natalizumab reduces visual loss in patients with relapsing multiple sclerosisNeurology68129930417438220
   PubMed Web of Science ®Google Scholar
• BalcerLJO’ConnorPWHavrdovaE2005The effects of natalizumab on disability progression as measured by the Multiple Sclerosis Functional Composite (MSFC) and visual function in patients with relapsing MSPresented at 18th World Congress of NeurologyNovember 9Sydney, Australia
   Google Scholar
• CalabresiPAGiovannoniGConfavreuxC2007The incidence and significance of anti-natalizumab antibodiesNeurology69139140317761550
   PubMed Web of Science ®Google Scholar
• CliffordDBYiannoutsosCGlickmanM1999HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathyNeurology52623510025799
   PubMed Web of Science ®Google Scholar
• Consortium of Multiple Sclerosis Centers Health Services Research Subcommittee1997Multiple Sclerosis Quality of Life Inventory: A User’s ManualNew YorkNational Multiple Sclerosis Society
   Google Scholar
• CrowderCDGyureKADrachenbergCB2005Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patientAm J Transplant51151815816900
   PubMed Web of Science ®Google Scholar
• Data on file2007Cambridge, MABiogen Idec, Inc.
   Google Scholar
• European Agency for the Evaluation of Medicinal Products2006Tysabri® summary of product characteristics.
   Google Scholar
• ffrench-ConstantC1994Pathogenesis of multiple sclerosisLancet34327157905102
   PubMed Web of Science ®Google Scholar
• FisherEO’ConnorPWHavrdovaE2006The effects of natalizumab on brain atrophy and cognitive function: results from the AFFIRM study [abstract]Mult Scler12suppl 1S103Abstract P383.
   Google Scholar
• GoldRJawadAMillerDH2007Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapiesJ Neuroimmunol187156817499366
   PubMed Web of Science ®Google Scholar
• HavrdovaEGiovannoniGHitchinsonM2007Natalizumab increases the proportion of patients with multiple sclerosis who are disease free [abstract]Mult Scler13suppl 2S170Abstract P567
   Google Scholar
• IFNB Multiple Sclerosis Study Group1993Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Clinical results of a multi-center, randomized, double-blind, placebo-controlled trialNeurology43655618469318
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRA1996Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosisAnn Neurol39285948602746
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJA1995Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trialNeurology451268767617181
   PubMed Web of Science ®Google Scholar
• KapposKBatesDHartungH-P2007Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoringLancet Neurol64314117434098
   PubMed Web of Science ®Google Scholar
• KhatriBFoxRKooA2007The effect of plasma exchange in accelerating clearance of natalizumab in patients with multiple sclerosis: results of the PLEX study [abstract]Mult Scler13Suppl 2S172Abstract P576.
   Google Scholar
• Kleinschmidt-DeMastersBKTylerKL2005Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosisN Engl J Med3533697415947079
   PubMed Web of Science ®Google Scholar
• Langer-GouldAAtlasSWBollenAW2005Progressive multifocal leukoencephalopathy in a patient treated with natalizumabN Engl J Med3533758115947078
   PubMed Web of Science ®Google Scholar
• LublinFDReingoldSC1996Defining the clinical course of multiple sclerosis: results of an international surveyNeurology46907118780061
   PubMed Web of Science ®Google Scholar
• MajorEOAmemiyaKTornatoreCS1992Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brainClin Microbiol Rev549731310438
   PubMed Web of Science ®Google Scholar
• McDonaldWICompstonAEdanG2001Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel in the Diagnosis of Multiple SclerosisAnn Neurol50121711456302
   PubMed Web of Science ®Google Scholar
• MillerDHSoonDFernandoKT2007MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MSNeurology68139040117452584
   PubMed Web of Science ®Google Scholar
• NoseworthyJHLucchinettiCRodriguezM2000Multiple sclerosisN Engl J Med3439385211006371
   PubMed Web of Science ®Google Scholar
• O’ConnorPWGoodmanAKapposL2007The efficacy of natalizumab monotherapy over 3 years of treatment in patients with relapsing multiple sclerosisNeurology68Suppl 1A275Abstract P06.082.
   Google Scholar
• PanzaraMABelcherGKooijmansM2007Use of natalizumab in patients with relapsing multiple sclerosis: updated safety results from TOUCH™ and TYGRIS [abstract]Mult Scler13Suppl 2S169Abstract P565.
   PubMedGoogle Scholar
• PhillipsJTKapposLO’ConnorPW2006The effects of natalizumab monotherapy on multiple measures of disability progression in patients with multiple sclerosisPresented at 58th Annual Meeting of the American Academy of NeurologyApril 4San Diego, CA
   Google Scholar
• PolmanCHO’ConnorPWHavrdovaE2006A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med35489991016510744
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group1998Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosisLancet35214985049820297
   PubMed Web of Science ®Google Scholar
• RudickRAAntelJAConfavreuxC1997Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task ForceAnn Neurol42379829307263
   PubMed Web of Science ®Google Scholar
• RudickRAFisherELeeJ-C1999Use of brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MSNeurology53169870410563615
   PubMed Web of Science ®Google Scholar
• RudickRAMillerDHassS2007Health-related quality of life in multiple sclerosis: effects of natalizumabAnn Neurol623354617696126
   PubMed Web of Science ®Google Scholar
• RudickRAStuartWHCalabresiPA2006Natalizumab plus interferon beta-1 for relapsing multiple sclerosisN Engl J Med3549112316510745
   PubMed Web of Science ®Google Scholar
• SchellekensHCasadevallN2004Immunogenicity of recombinant human proteins: causes and consequencesJ Neurol251Suppl 2II/2II/9
   Google Scholar
• ShitritDLevNBar-Gil-ShitritA2005Progressive multifocal leukoencephalopathy in transplant recipientsTranspl Int176586515616809
   PubMed Web of Science ®Google Scholar
• Tysabri® [prescribing information]2007Cambridge, MABiogen Idec, Inc.
   Google Scholar
• US Food and Drug Administration, Center for Drug Evaluation and Research, Peripheral and Central Nervous System (PCNS) Advisory Committee2006Briefing Document: Biogen Idec Biologics Marketing Application STN 125104/15, Natalizumab (Tysabri) for Multiple SclerosisSilver Spring, MDUS Department of Health and Human Services
   Google Scholar
• Van AsscheGVan RanstMSciotR2005Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s diseaseN Engl J Med353362815947080
   PubMed Web of Science ®Google Scholar
• WareJEJrSherbourneCD1992The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selectionMed Care304734831593914
   PubMed Web of Science ®Google Scholar
• YousryTAMajorEORyschkewitschC2006Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathyN Engl J Med3549243316510746
   PubMed Web of Science ®Google Scholar